Mammoth Biosciences Raises $195 Million to Build Next-Generation CRISPR Products in Therapeutics and Diagnostics

11 Sep, 2021

Mammoth Biosciences Raises $195 Million to Build Next-Generation CRISPR Products in Therapeutics and Diagnostics
Photo by Patrick Robert Doyle on Unsplash

– Mammoth Biosciences has secured $195m in financing, joining the select ranks of “unicorn” startups with a valuation of more than $1bn.
– The funds will enable the company to broaden its toolkit of next-generation CRISPR systems with a focus on building permanent genetic cures through in vivo gene-editing therapeutics and democratizing disease detection with on-demand diagnostics.
– Mammoth’s CRISPR platform leverages the largest toolbox of novel Cas enzymes, driven by its proprietary protein discovery engine which leverages the natural diversity of life.

Biotechnology Genetics Health Diagnostics Life Science North America
Crunchbase icon

Content report

The following text will be sent to our editors: